A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

CompletedOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Portopulmonary HypertensionPulmonary Arterial HypertensionPulmonary Hypertension
Interventions
DRUG

Treprostinil

"Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.~Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min."

Trial Locations (4)

30322

Emory Univeristy, Atlanta

75235

University of Texas, Southwestern Medical Center, Dallas

90024

University of California, Los Angeles, Los Angeles

02115

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

University of Texas

OTHER

collaborator

Emory University

OTHER

lead

United Therapeutics

INDUSTRY